Jefferies sees Radico Khaitan leading India’s premium alcobev growth cycle

Jefferies retained its Buy call on Radico Khaitan, citing vodka-led innovation, execution and favourable regulation. The brokerage set a ₹5,200 target price, implying more than 11% upside, and flagged potential benefits from an India-UK FTA.

— Source published Tue, 18 Aug, 2026, 08:16 IST · First seen Tue, 18 Aug, 2026, 09:10 IST · Source NDTV Profit

What happened

Jefferies expects Radico Khaitan to lead growth in India’s premium alcoholic-beverage segment, supported by vodka innovation, execution, regulatory conditions

Key facts

  • Target price: Rs 5,200
  • Implied upside: over 11%
  • Share gain: 14% in one month
  • Share gain: 66% in six months
  • Share gain: 64% in one year
  • Share gain: 180% in two years
  • Share gain: 408% over five years

Why this matters

Potential India-UK FTA benefits and favourable regulation could improve access to premium inputs and strengthen strategic partnership or portfolio-expansion opportunities.

What to watch

  • Quarterly premium-and-luxury portfolio volume growth versus mass-market growth.
  • Net sales realisation and gross-margin movement after marketing and input-cost changes.
  • New state excise policies, price approvals, distribution-rule changes and tax increases.
  • India-UK FTA progress and specific provisions affecting spirits, bulk Scotch, import duties or market access.
  • Competitive launch intensity and promotional spending in vodka, whisky and prestige categories.
  • Evidence that new launches gain repeat demand rather than only initial trade stocking.
  • Prioritise premium vodka and adjacent white-spirit launches with differentiated packaging and price ladders.
  • Deepen distribution in high-income urban and travel-retail channels where premium trial and repeat purchase are strongest.
  • Use any FTA-linked input-cost relief to protect margins while selectively reinvesting in brand building.
  • Increase investor focus on premium-volume growth, net realisation, EBITDA margin and state-wise regulatory exposure.